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Abstract
Purine cyclin-dependent kinase inhibitors have been recognized as promising candidates for the treatment of various
cancers; nevertheless, data regarding interaction of these substances with drug efflux transporters is still lacking. Recently,
we have demonstrated inhibition of breast cancer resistance protein (ABCG2) by olomoucine II and purvalanol A and shown
that these compounds are able to synergistically potentiate the antiproliferative effect of mitoxantrone, an ABCG2
substrate. In this follow up study, we investigated whether olomoucine II and purvalanol A are transported by ABCG2 and
ABCB1 (P-glycoprotein). Using monolayers of MDCKII cells stably expressing human ABCB1 or ABCG2, we demonstrated that
olomoucine II, but not purvalanol A, is a dual substrate of both ABCG2 and ABCB1. We, therefore, assume that
pharmacokinetics of olomoucine II will be affected by both ABCB1 and ABCG2 transport proteins, which might potentially
result in limited accumulation of the compound in tumor tissues or lead to drug-drug interactions. Pharmacokinetic
behavior of purvalanol A, on the other hand, does not seem to be affected by either ABCG2 or ABCB1, theoretically favoring
this drug in the potential treatment of efflux transporter-based multidrug resistant tumors. In addition, we observed
intensive sulfatation of olomoucine II in MDCKII cell lines with subsequent active efflux of the metabolite out of the cells.
Therefore, care should be taken when performing pharmacokinetic studies in MDCKII cells, especially if radiolabeled
substrates are used; the generated sulfated conjugate may largely contaminate pharmacokinetic analysis and result in
misleading interpretation. With regard to chemical structures of olomoucine II and purvalanol A, our data emphasize that
even drugs with remarkable structure similarity may show different pharmacokinetic behavior such as interactions with ABC
transporters or biotransformation enzymes.
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Introduction
Olomoucine II and purvalanol A are potent cyclin-dependent
kinase inhibitors (CDKi) that belong to the group of 2,6,9-
trisubstituted purine derivatives [1,2]. These compounds effec-
tively stop cellular proliferation, block transcription of essential
genes and induce apoptosis [3–5]. For their favorable pharmaco-
dynamic properties, purine CDKi have become modern alterna-
tives in cancer therapy [6,7]. Roscovitine (seliciclib, CYC202), a
structural analogue of olomoucine II and purvalanol A, has
reached phase II trials for treating various cancers [8,9]. Although
olomoucine II and purvalanol A are commonly considered
selective for cyclin-dependent kinases, several studies have
reported their subordinate intracellular targets from the super-
family of protein kinases, which are inhibited by these compounds
in the range of micromolar concentrations [3,10–13]. However,
possible interactions with other biological structures, such as drug
transporters, have not been properly investigated to date.
ATP-binding cassette transporters (ABC transporters) are
membrane proteins that pump many structurally unrelated
molecules, including drugs and toxins, out of cells. The most
widely studied members of this family, P-glycoprotein (ABCB1)
and breast cancer resistance protein (ABCG2), are abundantly
expressed in absorptive and eliminatory organs (e.g. small
intestine, liver, kidney) as well as in several blood-tissue barriers
(e.g. blood-brain barrier, placenta, blood-testis barrier) playing
crucial role in drug disposition [14,15]. In addition, by diminishing
intracellular concentrations of chemotherapeutics in cancer cells,
ABCB1 and ABCG2 transporters are frequently associated with
the multidrug resistance phenomenon [16,17]. Modulation of
these transporters is, therefore, of great clinical interest; ABC
transporter inhibitors have been investigated for their ability to
restore the sensitivity of tumor cells to chemotherapy or to increase
oral bioavailability and tissue penetration of ABC transporter
substrates [18–20]. Moreover, investigating interactions of novel
drug entities with transport proteins is an important issue in drug
discovery and development [21].
Recently, we have demonstrated inhibition of ABCG2 by
olomoucine II, purvalanol A, bohemine and roscovitine at in vitro
and in situ levels [22]. Olomoucine II and purvalanol A showed
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comparable or even higher potency than fumitremorgin C, a
model specific ABCG2 inhibitor. Moreover, using combination
method of Chou-Talalay, we demonstrated that these compounds
can synergistically potentiate the antiproliferative effect of
mitoxantrone, an ABCG2 substrate, in ABCG2-expressing cell
lines [22]. In the present paper, we employed transport assays in
MDCKII cells stably expressing ABCG2 or ABCB1 to investigate
whether transcellular passage of olomoucine II and purvalanol A is
affected by these transporters.
Materials and Methods
Reagents and Chemicals
Olomoucine II and purvalanol A were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Specific ABCG2 inhibitor,
fumitremorgin C, was supplied by Alexis Corporation (Lausanne,
Figure 1. Transport of olomoucine II at concentrations of 100 nM (A, B, C), 1 mM (D, E, F) and 10 mM (G, H, I) across monolayers of
MDCKII-ABCG2 (A, D, G), MDCKII-ABCB1 (B, E, H) and MDCKII-par (C, F, I) cells. 5 mM fumitremorgin C (FTC) was used as a specific ABCG2
inhibitor in MDCKII-ABCG2 cells. 1 mM LY335979 (LY) was employed as a specific ABCB1 and endogenous canine Abcb1 inhibitor in MDCKII-ABCB1
and MDCKII-par cells, respectively. Ratios of olomoucine II transport across cell monolayers (olomoucine II transport in basolateral to apical direction
divided by transport in apical to basolateral direction) with or without inhibitor were calculated two hours after olomoucine II addition and
statistically compared (see insets). Due to the generation of sulfated conjugate of olomoucine II, transport ratios were determined at 2 h interval to
reduce the misrepresenting effect of the metabolite. In basolateral to apical transport direction, olomoucine II was added into the basolateral
compartment and its concentrations were determined in the apical compartment. In the opposite transport direction, olomoucine II was applied into
the apical compartment and its concentrations were analyzed in the basolateral compartment.m, basolateral to apical transport without inhibitor;.,
apical to basolateral transport without inhibitor;n, basolateral to apical transport with inhibitor;,, apical to basolateral transport with inhibitor. Data
are expressed as means 6 SD of three independent experiments. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0075520.g001
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Switzerland). Specific ABCB1 inhibitor, LY335979, was obtained
from Toronto Research Chemicals (North York, ON, Canada).
Cell culture reagents were obtained from Sigma Aldrich (St. Louis,
MO, USA) and from Gibco BRL Life Technologies (Rockville,
MD, USA). Fluorescein isothiocyanate labeled dextran was from
Sigma-Aldrich (St. Louis, MO, USA). All other compounds and
agents were of analytical grade.
Cell Cultures
ABCG2- and ABCB1-transduced MDCKII sublines (MDCKII-
ABCG2 and MDCKII-ABCB1), which stably express ABCG2
and ABCB1 protein, respectively, were purchased from dr. Alfred
Schinkels lab (The Netherlands Cancer Institute, Amsterdam, The
Netherlands). These transduced sublines as well as the parental
MDCKII cell line (MDCKII-par) were routinely cultured in
complete Dulbecco’s modified Eagle’s medium with 10% fetal
bovine serum. 100 U/ml penicillin and 100 mg/ml streptomycin
were used while growing the cells on the membrane inserts. All
cells were routinely cultivated in antibiotic-free medium and
periodically tested for mycoplasma contamination. Stable expres-
sion of ABCB1 and ABCG2 was verified by qRT-PCR method
and by daunorubicin and mitoxantrone efflux activity, respective-
ly. Cells from passages 15 to 25 were used in all in vitro studies.
Dimethyl sulfoxide was applied as a CDKi solvent in concentra-
tions not exceeding 0.1%.
Cellular Monolayer Transport Assay
Transport assays were performed on microporous polycarbon-
ate membrane inserts (3 mm pore size, 24 mm diameter;
Transwell 3414, Costar, Cambridge, MA, USA) as described
previously [22]. MDCKII-ABCG2, MDCKII-ABCB1 or
MDCKII-par cells were seeded at a density of 16106 per insert
72 h before experiment. The medium was replaced after 24 and
48 h of cultivation. One hour before the start of the experiment,
the cells were washed with prewarmed 16phospate buffered saline
on both the apical and basal sides and Opti-MEM with or without
fumitremorgin C or LY335979 was added into both compart-
ments. At time 0, the experiment was started by replacing the
medium with fresh Opti-MEM with or without CDKi and
fumitremorgin C or LY335979 in the appropriate chamber.
Samples were taken every 2 h from the opposite chambers for the
duration of the experiment (6 h). Concentration of CDKi was
determined via HPLC/MS analysis. Immediately after the
experiment, cellular monolayer integrity was examined using
fluorescein isothiocyanate labeled dextran (MW=40 kDa). Dex-
tran leakage was accepted up to 1% per hour.
HPLC/MS Analysis
HPLC/MS analysis using LC 20A Prominence chromato-
graphic system (Shimadzu, Kyoto, Japan) coupled with LCQ Max
advantage mass spectrometer (Thermo Finnigan, San Jose, CA,
Figure 2. Mass spectra of an unknown peak eluted in the fifth minute of HPLC analysis of olomoucine II transport. (A) spectrum in
positive mode, (B) MS2 in positive mode, (C) negative mode, (D) MS2 in negative mode. Based on the nominal mass shift (+80 Da) from parent
compound and the collision spectra in negative as well as positive mode the compound was identified as a sulfated conjugate of olomoucine II.
doi:10.1371/journal.pone.0075520.g002
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USA) was used for the quantification of olomoucine II and
purvalanol A. The separation was performed on a Hypersil
GOLD C18 column (10064.6 mm, particle size 3 mm) protected
with an OPTI-GUARD 1 mm guard column C18. The mobile
phase flow rate was 0.35 ml/min and the column temperature was
maintained at 40uC. The data were processed using Xcalibur 2.0
software (Thermo Finnigan, San Jose, CA, USA).
Optimal separation of olomoucine II was achieved in mobile
phase containing the mixture of methanol and 0.0125% formic
acid (62:38, v/v). Bohemine was added to samples as the internal
standard (IS). Retention times were 5.5 and 6.5 min for IS and
olomoucine II, respectively. The detector was set as follows: spray
voltage of 4.5 kV, capillary temperature of 320uC, sheet and
auxiliary gas flows of 30 and 12 arbitrary units, respectively. The
chromatograms were recorded in SRM mode using precursor ion
at [M+H]+ (m/z: 371 olomoucine II and 341 IS) and the product
ions 265 (olomoucine II) and 250 (IS) were used for quantification
after collision dissociation. The collision energies were 38% and
40% for olomoucine II and IS, respectively. The linearity of the
method was evaluated in the range of 5–500 mM (r2 = 0.9961); the
method precision and accuracy were evaluated at 500, 100, 10 and
5 nM. The sample stability was evaluated within 94 h.
A mixture of methanol and 0.01% acetic acid (75:25 v/v) was
used for the separation of purvalanol A. Roscovitine was utilized as
the IS. Retention times were 5.7 and 9.2 min for IS and
purvalanol A, respectively. The detector was set as follows: spray
voltage of 5.5 kV, capillary temperature of 340uC, sheet and
auxiliary gas flows of 28 and 13 arbitrary units, respectively. The
chromatograms were recorded in SRM mode using precursor ion
at [M+H]+ (m/z: 389 purvalanol A and 355 IS) and the product
ions 303 (purvalanol A) and 312 (IS) were used for the
quantification after collision dissociation. The collision energies
were 38% and 40% for purvalanol A and IS, respectively. The
linearity of the method was evaluated in the range of 15–384 mM
(r2= 0.9925); the method precision and accuracy were evaluated at
384, 100 and 15 nM. The sample stability was evaluated within 94
hours.
Figure 3. Chromatograms of samples from MDCKII-par cells six hours after olomoucine II addition. (A) olomoucine II was added into
apical compartment while olomoucine II and its sulfated conjugate were analyzed in acceptor basolateral compartment, (B) olomoucine II was added
into apical compartment while olomoucine II and its sulfated conjugate were analyzed in donor apical compartment, (C) olomoucine II was added
into basolateral compartment while olomoucine II and its sulfated conjugate were analyzed in acceptor apical compartment, (D) olomoucine II was
added into basolateral compartment while olomoucine II and its sulfated conjugate were analyzed in donor basolateral compartment. This analysis
with end point samples was performed for all olomoucine II transport experiments.
doi:10.1371/journal.pone.0075520.g003
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Statistical Analysis
Student’s t test was used to assess statistical significance for
in vitro monolayer transport assays. Differences of p,0.05 were
considered statistically significant.
Results
Effect of ABCG2 and ABCB1 on the Transepithelial
Transport of Olomoucine II In Vitro
Transport of olomoucine II by ABCG2 and ABCB1 was tested
in vitro using transport assays across the polarized monolayers of
MDCKII-ABCG2 and MDCKII-ABCB1 cells, respectively. In
this method, the transport across the monolayer is greatly
accelerated in the basolateral to apical direction, when the
compound is a substrate of examined transporter. Based on our
Figure 4. Time-dependent generation of sulfated conjugate of olomoucine II in MDCKII-ABCG2 (A, D, G), MDCKII-ABCB1 (B, E, H)
and MDCKII-par (C, F, I) cells and its distribution into the apical and basolateral compartments. Relative quantification of sulfated
olomoucine II was calculated as a ratio between peak area of sulfated olomoucine II and the peak area of internal standard (IS). 5 mM fumitremorgin C
(FTC), a specific ABCG2 inhibitor, was used in MDCKII-ABCG2 cells for the assessment of possible involvement of ABCG2 in the transport of sulfated
metabolite. 1 mM LY335979 (LY) was employed as a specific ABCB1 and endogenous canine Abcb1 inhibitor in MDCKII-ABCB1 and MDCKII-par cells,
respectively. Data come from transport experiments with olomoucine II at concentrations of 100 nM (A, B, C), 1 mM (D, E, F) and 10 mM (G, H, I). In
basolateral to apical transport direction, olomoucine II was added into the basolateral compartment and its sulfate conjugate was determined in the
apical compartment. In the opposite transport direction, olomoucine II was applied into the apical compartment and its sulfated metabolite was
analyzed in the basolateral compartment.m, transport into apical compartment without inhibitor;., transport into basolateral compartment without
inhibitor; n, transport into apical compartment with inhibitor; ,, transport into basolateral compartment with inhibitor. Values are expressed as
means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0075520.g004
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Figure 5. Transport of purvalanol A at concentrations of 1 mM (A, B, C) and 10 mM (D, E, F) across monolayers of MDCKII-ABCG2 (A,
D), MDCKII-ABCB1 (B, E) and MDCKII-par (C, F) cells. 5 mM fumitremorgin C (FTC) was used as a specific ABCG2 inhibitor in MDCKII-ABCG2
cells. 1 mM LY335979 (LY) was employed as a specific ABCB1 inhibitor in MDCKII-ABCB1 cells. Ratios of purvalanol A transport across cell monolayers
(purvalanol A transport in basolateral to apical direction divided by transport in apical to basolateral direction) with or without inhibitor were
calculated and statistically compared (see insets). Transport ratios were determined 6 h after purvalanol A addition. In basolateral to apical transport
direction, purvalanol A was added into the basolateral compartment and its concentrations were determined in the apical compartment. In the
opposite transport direction, purvalanol A was applied into the apical compartment and its concentrations were analyzed in the basolateral
compartment. m, basolateral to apical transport without inhibitor; ., apical to basolateral transport without inhibitor; n, basolateral to apical
transport with inhibitor; ,, apical to basolateral transport with inhibitor. Data are expressed as means 6 SD of three independent experiments.
doi:10.1371/journal.pone.0075520.g005
Figure 6. Schematic depiction of olomoucine II and purvalanol A transport in transduced MDCKII cells. Transport pathways for CDKi are
indicated according to the results from MDCKII cellular monolayer transport assays. Transporter denoted with interrogation mark is unknown canine
transporter.
doi:10.1371/journal.pone.0075520.g006
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previous studies [22], three olomoucine II concentrations
(100 nM, 1 mM and 10 mM) were tested and transport ratios (r;
olomoucine II transport in basolateral to apical direction divided
by transport in apical to basolateral direction) 2 h after
olomoucine II addition were calculated. In contrast to purvalanol
A, the interval for data evaluation was shortened due to the
generation of sulfated metabolite of olomoucine II (see below).
Using olomoucine II in concentrations of 100 nM or 1 mM,
similar r values equal to 2.27 and 2.31 were observed in MDCKII-
ABCG2 cells, respectively. Fumitremorgin C, a specific ABCG2
inhibitor [23], significantly lowered asymmetry in olomoucine II
transport to r values of 1.32 and 1.21, respectively, thereby
confirming the involvement of ABCG2 in the transport of
olomoucine II (Fig. 1A, 1D). When 10 mM olomoucine II was
used, r decreased to 1.29, indicating transporter saturation
(Fig. 1G).
In MDCKII-ABCB1 cells, asymmetry in olomoucine II
transport was approximately 3-fold higher (r=6.45 and 6.83 for
100 nM and 1 mM, respectively) in comparison with ABCG2
transduced cells. LY335979, a specific ABCB1 inhibitor [24,25],
significantly reduced r to values similar to those observed in the
case of parent MDCKII cells (r=1.48 and 1.83 for 100 nM and
1 mM, respectively) (Fig. 1B, 1E). At 10 mM concentration, r
decreased to 2.51 indicating partial saturation of ABCB1
transporter (Fig. 1H). These results clearly demonstrate that
olomoucine II is a substrate of ABCB1 in vitro.
In MDCKII-par cells, slight transport asymmetry was found
with r values of 1.45, 1.39 and 1.64 for 100 nM, 1 mM and 10 mM
olomoucine II, respectively (Fig. 1C, 1F, 1I). Since MDCKII-par
cells express significant amount of endogenous canine Abcb1
[26,27], we investigated its possible role in this basal transport by
adding LY335979 inhibitor. However, we did not observe
statistically significant changes in r values for 100 nM and 1 mM
olomoucine II, suggesting no or negligible participation of
endogenous canine Abcb1 in olomoucine II transport (Fig. 1C,
1F).
Generation of Sulfated Conjugate of Olomoucine II and
its Pharmacokinetic Behavior in MDCKII Cells
In olomoucine II transport experiments, we recorded time-
dependent generation of an unknown peak in the fifth minute of
HPLC analysis in all three cell lines tested (MDCKII-ABCG2,
MDCKII-ABCB1 and MDCKII-par). Based on the MS analysis
[28], the compound was identified as a sulfated conjugate of
olomoucine II (Fig. 2). Importantly, equilibrium of sulfate
conjugate distribution into particular compartments did not
significantly differ when the parent compound was added into
the basal or apical compartment (Fig. 3). On the other hand, the
amount of sulfated metabolite increased with time and caused
remarkable distortion of the results of parent compound.
Therefore, when analyzing the data of unconjugated olomoucine
II, the time interval was shortened to 2 hours in order to reduce
the misrepresenting effect of sulfated olomoucine II. Considering
ionic nature of sulfated olomoucine II, it is obvious that this
compound cannot escape from the cells via passive diffusion but
must utilize special transport system(s). Relative quantification of
olomoucine II sulfate allowed us to describe its pharmacokinetic
behavior in all MDCKII cell sublines.
In MDCKII-ABCG2 cells at 100 nM olomoucine II concen-
tration, the sulfate appearance in apical compartment was
markedly higher than that in basolateral compartment. After
addition of fumitremorgin C, efflux into apical compartment was
fully blocked whereas transport into opposite compartment
significantly increased (Fig. 4A). Similar outcome was recorded
in the case of 1 mM olomoucine II (Fig. 4D). These data
demonstrate the contribution of ABCG2 to the efflux of sulfated
olomoucine II through the apical membrane of MDCKII-ABCG2
cells. At 10 mM concentration, we observed identical appearance
of sulfated conjugate in both compartments (Fig. 4G), suggesting
saturation of ABCG2.
In MDCKII-ABCB1 cells at 100 nM and 1 mM olomoucine II,
distribution of sulfated olomoucine II into basolateral and apical
compartments was almost identical. This equilibrium was notably
changed after LY335979 co-administration which increased
appearance of the conjugate in the basolateral, but not apical,
compartment (Fig. 4B, 4E). This phenomenon can be explained by
LY335979-induced inhibition of ABCB1 which results in higher
intracellular concentrations of olomoucine II and, therefore,
greater availability of the drug for sulfatation. Generated
olomoucine II sulfate is eventually transferred into basolateral
compartment, most likely by endogenous canine transporters
reported in MDCKII cells [26]. Sulfate distribution ratio after
LY335979 addition in MDCKII-ABCB1 cells was almost identical
to that observed in MDCKII-par, supporting this hypothesis.
Transport of olomoucine II sulfate in MDCKII-par cells,
expressing only endogenous canine transporters, was markedly
forced into the basolateral compartment whereas only limited
amount reached the apical one. Addition of LY335979 did not
affect this asymmetry, excluding the role of canine Abcb1 in the
process (Fig. 4C, 4F, 4I). We, therefore, speculate that a transport
system located in the basolateral membrane is the key player
affecting metabolite distribution in non-transduced cells.
Effect of ABCG2 and ABCB1 on the Transepithelial
Transport of Purvalanol A In Vitro
Possible involvement of ABCG2 and/or ABCB1 in the
transcellular transport of purvalanol A was examined employing
cellular monolayer transport assays with MDCKII-ABCG2 and
MDCKII-ABCB1 cells, respectively. Based on our previous studies
[22], two purvalanol A concentrations (1 mM and 10 mM) were
tested and transport ratios (r; purvalanol A transport in basolateral
to apical direction divided by transport in apical to basolateral
direction) at the end of the experiment were calculated.
In contrast to olomoucine II, only negligible asymmetry in
purvalanol A transport was observed in MDCKII-ABCG2 cells
with r of 1.28 and 1.23 for 1 mM and 10 mM, respectively. No
changes were recorded after concomitant addition of fumitremor-
gin C (r=1.33 and 1.26 for 1 mM and 10 mM, respectively)
(Fig. 5A, 5D). These results demonstrate that purvalanol A is not
an ABCG2 substrate in vitro.
Similar results were obtained in MDCKII-ABCB1 cells; only
negligible asymmetry in purvalanol A transport was observed,
Figure 7. Chemical structures of olomoucine II and purvalanol
A.
doi:10.1371/journal.pone.0075520.g007
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reaching r values of 1.36 and 1.26 for 1 mM and 10 mM,
respectively. Addition of LY335979 did not affect r values (1.20
and 1.18 for 1 mM and 10 mM, respectively) (Fig. 5B, 5E). These
patterns of transport clearly demonstrate that purvalanol A is not
an ABCB1 substrate.
As expected, only negligible asymmetry in purvalanol A
transport was observed in MDCKII-par cells. 1 mM and 10 mM
purvalanol A concentrations yielded r values of 1.14 and 1.05,
respectively (Fig. 5C, 5F).
Interestingly, no fragments corresponding to sulfated purvalanol
A were recorded in MS analysis indicating that, in contrast to
olomoucine II, purvalanol A is not subjected to sulfatation in
MDCKII cells.
Discussion
Purine CDKi have recently been recognized as promising
candidates for the treatment of various cancers [6]. While
pharmacodynamic properties of these compounds are relatively
well understood, their pharmacokinetic behavior and interactions
with other biological structures, such as transport proteins and
biotransformation enzymes have not been properly investigated to
date. Bachmaier and Miller were the first to observe interactions of
purine CDKi with ABC transporters and demonstrated significant
inhibition of ABCB1 by roscovitine in bovine brain microvessel
endothelial cell monolayers [29]. More recently, An et al. revealed
ABCG2 inhibition by purvalanol A, WHI-P180, roscovitine and
bohemine employing in vitro hematoporphyrin transport across
membrane vesicles from insect Sf9 cells transduced with ABCG2
[30]. In our previous work, we observed ABCG2 inhibition by
olomoucine II and purvalanol A on in vitro as well as in situ level.
Moreover, using combination method of Chou-Talalay, we
demonstrated that these compounds can synergistically potentiate
the cytostatic effect of mitoxantrone, an ABCG2 substrate, in
ABCG2 expressing cell lines [22].
In the present study, we investigated whether olomoucine II and
purvalanol A are transported by ABCG2 and/or ABCB1. To
date, only one paper has reported on substrate affinity of purine
CDKi toward ABC transporters; using ATPase assay, vesicular
transport, Hoechst 33342 and calcein assays, Rajnai et al. [31]
demonstrated roscovitine to be a high affinity ABCB1 substrate
and suggested that this interaction may be the reason for limited
penetration of roscovitine across the blood-brain barrier. In
addition, these authors concluded that roscovitine is not
transported by ABCG2, multidrug resistance associated protein
1 (ABCC1) and multidrug resistance associated protein 2
(ABCC2). In our current work, using cellular monolayer transport
assays with ABCG2 and ABCB1 transduced MDCKII cells, we
demonstrate that olomoucine II is a dual substrate of ABCG2 and
ABCB1 (Fig. 6). Based on our findings, it is feasible to presume
considerable effect of both transporters on the pharmacokinetic
behavior of olomoucine II, including absorption, distribution and
excretion as well as limited uptake by tumors overexpressing
ABCG2 and ABCB1. In addition, drug interactions with other
substrates of these transporters must be considered in clinical use.
In contrast to olomoucine II, we show that purvalanol A is not
transported by ABCG2 and ABCB1 in vitro (Fig. 6). In accordance
with these results, we suggest that pharmacokinetic behavior and
tumor treating abilities of purvalanol A will not be affected by
ABCG2 and/or ABCB1. These findings may, at least partly,
explain negligible resistance of ABCG2 overexpressing HeLa-6621
cells to purvalanol observed by Seamon et al. [32].
While investigating transport of olomoucine II across MDCKII
monolayers, we detected time-dependent generation of a metab-
olite that we characterized as a sulfated conjugate of olomoucine II
(Fig. 6). Enormous sulfatation capacity of MDCKII cells,
significantly exceeding that of human liver, Chang liver and
HepG2 cells, has previously been reported by Ng et al. [33]. Since
transduced MDCKII cell lines are a well-established and widely
used model in drug development for investigation of drug
interactions with transport proteins [21], our findings are of great
importance for other researchers performing transport or accu-
mulation studies with MDCKII cells, especially if radiolabeled
substrates are used. It is very likely that hydrophilic metabolites
(sulfates) formed during the experiment will follow transport
pathway(s) different from the parent compound and, eventually,
may contaminate the pharmacokinetic analysis. Several endoge-
nous canine transporters, such as Abcb1, Abcc1, Abcc2, and
Abcc5, have been localized in the MDCKII cells [26,27], of which
multidrug resistance associated proteins can transport sulfated
metabolites. We, therefore, assume that in our experiments,
endogenous canine Abcc1, Abcc2 or Abcc5 transporters might
efflux sulfated olomoucine II out of the MDCKII cells.
ABC transporters are well known for their ability to transport a
wide variety of structurally unrelated molecules. Considering very
similar structures of olomoucine II and purvalanol A (Fig. 7), it is
surprising to see strikingly different interactions of both com-
pounds with ABCB1 and ABCG2 proteins; only olomoucine II,
but not purvalanol A, is transported by these transporters as
observed in this study. However, our results correspond nicely with
the studies by Ishikawa et al [34] or Nakagawa et al [35] who
prepared several camptothecine analogues and tested them for
their ability to circumvent the drug resistance mediated by
ABCG2. The authors observed that analogues substituted with
hydroxyl group were good ABCG2 substrates whereas replace-
ment of the hydroxyl group with chlorine led to a remarkable
reduction in affinity toward ABCG2. Correspondingly, olomou-
cine II (possessing hydroxyl group on the phenylamine substituent
of purine heterocycle) was found to be a substrate of both ABC
transporters in our study; on the other hand, purvalanol A (with –
OH group replaced by chlorine) (Fig. 7) was not transported by
any of the ABC transporters, suggesting that these two substituents
play a key role in the recognition of the purine CDKi as ABC
transporter substrates. Apart from in vitro experiments, we have
confirmed identical behavior of both compounds on an organ level
in situ; in perfused rat placenta, olomoucine II was actively pumped
from fetus to mother by placental ABCB1/ABCG2 while
purvalanol A showed no interactions with these transporters (data
not shown) proposing our findings can be extrapolated beyond the
in vitro experimental setup. It is thus apparent that structure
similarity of particular CDKi cannot be used as a single reliable
clue for the prognosis of interactions with ABC transporters.
Conclusions
In conclusion, our data suggest that pharmacokinetic behavior
of olomoucine II in the organism will be considerably affected by
ABCG2 and ABCB1 transporters as well as by phase II
biotransformation enzyme, sulfotransferase. Limited accumulation
of olomoucine II in tumors overexpressing ABCG2 and ABCB1
can also be expected. At the same time, overlapping substrate
specificity with other drugs may lead to drug-drug interactions on
these transporters. In contrast, pharmacokinetic behavior of
purvalanol A is not affected by either ABCG2 or ABCB1,
theoretically favoring this drug in the treatment of tumors
expressing efflux transporters. These facts should be taken into
account when introducing these prospective compounds into the
clinical area. In addition, care should be taken when performing
Olomoucine II Transport by ABCG2 and ABCB1
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pharmacokinetic studies in MDCKII cells, especially if radiola-
beled substrates are used; sulfated conjugates formed within the
cells may use other transport systems than the parent compound,
which can eventually result in misleading interpretation of the
pharmacokinetic analysis. With regard to chemical structures of
olomoucine II and purvalanol A, our data emphasize that even
drugs with remarkable structure similarity may show different
pharmacokinetic behavior such as interactions with ABC trans-
porters or biotransformation enzymes.
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